RE:AstraZeneca's ADC disappoints - on severe adverse eventsOn Friday April 05, 2024, Enhertu became the first tumor-agnostic HER2-directed therapy authorized for administration, and the first antibody-drug conjugate (ADC) to win such an indication.
Data from the Phase 2 Destiny study showed that in HER2-positve solid tumors, Enhertu had an ORR of 37.1% after a median follow-up of 12.75 months, while its overall DOR was 11.3 months.
https://www.biospace.com/article/astrazeneca-daiichi-sankyo-win-first-tumor-agnostic-her2-fda-approval-for-enhertu/